B-BIC Collaborative

Coaching

Rolling Applications

Non-Dilutive

Proposals Received

Member Institution

Clinical Area

Technology Type

Awards Granted

Institution

Clinical Area

Technology Type

Jonathan Thon

A Biomimetic Human Platelet Bioreactor

BWH

Blood

Therapeutic Device

Seemantini Nadkarni

A Blood Coagulation Sensor for Point of Care Use

MGH

Blood

Diagnostic Device

Eric Gale

A Manganese Alternative To Gadolinium for MRI Contrast

MGH

Blood

Diagnostic Device

Leo Tsai

A Novel Coaxial Deflectable Microcatheter for Rapid Navigation of Tortuous Vessels

BIDMC

Other

Therapeutic Device

Brian McAlvin

A Novel Method to Treat the Systemic Inflammatory Response Syndrome (SIRS)

BCH

Blood

Therapeutic Device

Mei Wu

A Prototype Laser Device for Treatment of Thrombocytoenia

MGH

Blood

Therapeutic Device

Daniel Irimia

Accurate Sepsis Diagnostic Using a Neutrophil Microfluidic Device

MGH

Blood

Diagnostic Device

Gary Gilbert

Activated Platelet Time: An Improved Factor VIII Assay

Harvard

Blood

Other

Brian Polizzotti

Advanced Development of Intravenous Oxygen Microparticles

BCH

Lung

Therapeutic Device

Darren Roblyer

CardioptOx: A New Real-time Quantitative Cardio-pulmonary Monitoring Technique for Improved Patient Care

BU/BMC

Heart

Diagnostic Device

Aditya Kaza

Confocal Microscopy for Intraoperative Discrimination of Cardiac Conduction Tissue

BCH

Heart

Therapeutic Device

Ali Khademhosseini

Developing a Biocompatible Elastic Sealant

BWH

Lung

Therapeutic Device

Nikolay Vasilyev

Development of an Implantable Intracardiac Soft Robotic Right Ventricular Ejection Device

BWH

Heart

Therapeutic Device

Luigi Taranto-Montemurro

Efficacy of Yohimbine as a Drug Treatment for Obstructive Sleep Apnea

BWH

Sleep

Small Molecule Drug

Warren Zapol

Electric Nitric Oxide Generation for Medical Purposes

MGH

Lung

Therapeutic Device

John Connor

Elimination of Pathogenic IgE in Cystic Fibrosis

BU/BMC

Lung

Biologic Drug

Nelson Ruiz-Opazo

Fully Humanized Anti-DEpR Antibody Therapy for Acute Lung Injury / Acute Respiratory Distress

BU/BMC

Lung

Biologic Drug

Jonghan Kim

Hydrogel-based Nanochelator Therapy for Iron Overload Disorders

NEU

Blood

Small Molecule Drug

Xin Zhang

Impedance-Based, Continuous Hematocrit Monitoring in the Trauma Population

BU/BMC

Blood

Diagnostic Device

Ehud Schmidt

Intracardiac MRI Ablation-Monitoring Catheter

BWH

Heart

Diagnostic Device

Anders Naar

MicroRNA Antisense Therapeutics in Cardiometabolic Diseases

MGH

Heart

Biologic Drug

Elazer Edelman

Minimally Invasive Tissue Engineering Therapies for Acute Airway Injury

MIT

Lung

Therapeutic Device

Paul Yu

Molecular Imaging of Dysregulated Angiogenesis in Pulmonary Arterial Hypertension

BWH

Lung

Diagnostic Device

Ehud Schmidt

MRI-Compatible Voltage Device Tracking for Multimodality Electrophysiology

BWH

Heart

Therapeutic Device

Edgar Milford

Novel Antibody Targeting Approach for the Treatment of Idiopathic Pulmonary Fibrosis

BWH

Lung

Biologic Drug

Karin Hoffmeister

Novel Approaches for Platelet Storage

BWH

Blood

Other

David Milan

Novel Treatment for Long QT Syndrome

MGH

Heart

Small Molecule Drug

Jonghan Kim

Pharmacokinetics of Multifunctional Nanochelators in Iron Overload Disorders

NEU

Blood

Small Molecule Drug

Samuel Patz

Portable MR Device for the Pulmonary ICU

BWH

Lung

Diagnostic Device

Benjamin Matthews

PR1P, an Inhaled Novel Short Peptide for Acute Lung Injury and ARDS

BCH

Lung

Small Molecule Drug

Benjamin Matthews

PR1P, an Inhaled Novel Short Peptide for Emphysema

BCH

Lung

Small Molecule Drug

Sylvie Breton

Predicting and Preventing Acute Kidney Injury Associated with Cardiovascular Diseases

MGH

Heart

Small Molecule Drug

Matthew Spite

Pro-Resolving Micro-/Nano-Particles to Improve Vascular Patency

BWH

Blood

Therapeutic Device

Gabriel Gruionu

Rapid Perfusion Catheter

MGH

Blood

Therapeutic Device

Bruce Bean

Silencing Airway Nociceptors for Treatment of Cough and Airway Inflammation

HMS

Lung

Small Molecule Drug

Michael Sweeney

SQPAN

BWH

Heart

Therapeutic Device

Pamela Silver

Targeting Erythropoietin-Based Therapeutics

Harvard

Blood

Biologic Drug

Jason Fiering

Therapeutic Apheresis by Microfluidic Acoustic Separation

Draper

Blood

Therapeutic Device

Leo Tsai

Variable Stiffness Microcatheter for Navigation of Tortuous Vessels

BIDMC

Other

Therapeutic Device

Funding Programs

Pilot Grants

Pilot awards support projects to demonstrate proof of concept, such as prototype development, or reproducibility experiments in different model systems. Pilot awards provide up to $88,750 total cost. (Indirect costs are provided at the applicant institution’s negotiated Federal rate.) Pilot projects are expected to be completed within one year.

DRIVE Grants

DRIVE awards are provided as investments in early-stage technologies that have the potential for commercial translation within two years. DRIVE awards provide up to $350,000 total cost to support proof-of-value studies. (Indirect costs are provided at the applicant institution’s negotiated Federal rate.)

Areas of Interest

B-BIC will select early stage technologies that address unmet medical needs or offer great scientific opportunities with either immediate commercial potential or otherwise present compelling reasons for continued development. B-BIC is currently focused on innovative devices, diagnostics, and therapeutics related to heart, lung, blood, and sleep disorders. Program priority areas include, but are not limited to, the following:

Cardiovascular Diseases

Heart failure, atherothrombosis, myocardial infarction, hypertension, atrial fibrillation along with other atrial and ventricular arrhythmias, sudden cardiac death, adult and pediatric congenital heart disease, cardiovascular complications of diabetes and obesity, acquired valve disease, cardiomyopathies, and peripheral vascular diseases.

Lung Diseases and Sleep Disorders

Asthma, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, cystic fibrosis, respiratory neurobiology, sleep-disordered breathing, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunologic and fibrotic pulmonary disease, rare lung disorders, pulmonary vascular disease, and pulmonary complications of AIDS and tuberculosis.

Blood Diseases and Resources

Sickle cell disease (SCD), the thalassemias, Fanconi anemia, Diamond-Blackfan anemia and other bone marrow failure syndromes, iron metabolism, fetal hemoglobin production, white blood cell disorders, myeloproliferative and myelodysplastic syndromes, hematopoietic stem cell transplantation and novel cell-based therapies, transfusion medicine (red blood cells, platelets, and plasma) and blood banking including technologies to store and process blood, thrombosis and hemostatic disorders including but not limited to idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), hemophilia, and coagulation factor deficiencies and disorders.

The Process

Eligibility

Faculty from the B-BIC member institutions are eligible to apply.
For-profit entities are eligible to apply as collaborators with Principal Investigators at member institutions.
The proposed work must support the advancement of technology that is owned by a B-BIC member institution.

Budget Considerations

Applications to the Pilot program may request up to $50,000 direct.
Applications to the DRIVE program may request up to $200,000 direct.
For awards supported with Federal dollars, indirect costs are provided at the applicant institution’s negotiated Federal rate on top of direct costs.
The current NIH salary cap must be applied to personnel costs.
B-BIC supports the advancement of technology towards commercial development. Funds are not awarded for the purchase of equipment, travel, or publication costs except under unusual circumstances.
DRIVE awards will be released in accordance with milestone and tranche plans included with the application.

Deadlines and Proposal Review

Pre-proposals may be submitted anytime throughout the year. There is no set deadline for submissions.
A subset of applicants who submit pre-proposals will be invited to develop full proposals.
Full proposals are reviewed on a rolling basis by members of the B-BIC External Selection Committee, including representatives from the local life sciences and venture capital communities. Full proposals are also reviewed by our Federal Partners, including representatives from the USPTO, FDA, CMS, and payor/provider organizations. To minimize the time between full proposal submission and funding decision, the optimal times to submit full proposal are mid-January, mid-April, mid-July, and mid-October.

Format

All pre-proposals and full proposals must be submitted using the online application system at b-bic.fluidreview.com.

All required supporting documents, including the B-BIC budget form, compliance, form, NIH biosketches, and institutional authorization must be uploaded into the online application system.

All text material must be in a readable font (at least Arial 10 point), and margins must be at least 0.5 inches.

Pre-Proposal Form

Full Proposal Form

Full Proposal Review Criteria